Exelixis, Inc. (NASDAQ:EXEL) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Exelixis, Inc. (NASDAQ:EXEL) have received a consensus recommendation of “Moderate Buy” from the twenty-eight analysts that are currently covering the company, Marketbeat reports. Twelve investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $45.45.

EXEL has been the subject of several research analyst reports. Royal Bank Of Canada restated a “sector perform” rating and set a $45.00 price target on shares of Exelixis in a research note on Tuesday, October 21st. Guggenheim cut Exelixis from a “buy” rating to a “neutral” rating in a report on Monday, November 3rd. Morgan Stanley raised their price target on shares of Exelixis from $44.00 to $45.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Citigroup reaffirmed a “market outperform” rating on shares of Exelixis in a research report on Tuesday, October 21st. Finally, Cowen reissued a “buy” rating on shares of Exelixis in a research report on Wednesday, November 5th.

Insider Buying and Selling at Exelixis

In other Exelixis news, EVP Dana Aftab sold 48,383 shares of the firm’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $42.50, for a total value of $2,056,277.50. Following the transaction, the executive vice president directly owned 664,778 shares of the company’s stock, valued at $28,253,065. This trade represents a 6.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Mary C. Beckerle sold 24,622 shares of the business’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $41.93, for a total value of $1,032,400.46. Following the transaction, the director owned 21,380 shares in the company, valued at approximately $896,463.40. This represents a 53.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 245,235 shares of company stock valued at $10,490,600 in the last quarter. Company insiders own 2.82% of the company’s stock.

Institutional Trading of Exelixis

A number of hedge funds have recently made changes to their positions in EXEL. Richardson Financial Services Inc. boosted its position in Exelixis by 95.1% in the 3rd quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 292 shares during the last quarter. Anchor Investment Management LLC lifted its stake in shares of Exelixis by 500.0% in the third quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 500 shares in the last quarter. Hemington Wealth Management boosted its holdings in Exelixis by 211.3% in the first quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 522 shares during the last quarter. Root Financial Partners LLC purchased a new position in Exelixis in the third quarter valued at about $28,000. Finally, Byrne Asset Management LLC grew its stake in Exelixis by 129.0% during the 2nd quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Stock Performance

Shares of EXEL stock opened at $44.12 on Wednesday. The firm has a market capitalization of $11.83 billion, a price-to-earnings ratio of 21.21, a price-to-earnings-growth ratio of 0.79 and a beta of 0.32. Exelixis has a one year low of $31.90 and a one year high of $49.62. The company has a 50 day moving average price of $40.24 and a 200 day moving average price of $40.88.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.10. The company had revenue of $597.76 million during the quarter, compared to analysts’ expectations of $590.04 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The business’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.47 EPS. Exelixis has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Exelixis will post 2.04 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.